You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 君實生物(1877.HK)逆勢上漲5.53% 研發新冠病毒中和抗體
格隆匯 06-15 10:49
格隆匯6月15日丨市場憂北京疫情重燃,君實生物(1877.HK)逆勢上漲5.53%,報54.4港元,總市值426.6億港元。全國昨日新增確診49例,北京新增本土病例36例。國務院副總理孫春蘭14日召開國務院聯防聯控機制會議強調,此次聚集性疫情與新發地農產品批發市場高度關聯,市場人員密集、流動性大,疫情擴散的風險很高。瑞信發表研究報告,指出君實生物(1877.HK)旗下的重組全人源抗SARS-CoV-2單克隆抗體注射液(項目代號:JS016)成為中國最早進入臨牀階段的新冠病毒中和抗體。該行指,由於疫情仍然持續,並有機會在今年秋冬季迎來第二波爆發,認為JS016的商業機會龐大,有望為君實生物2020至2021年帶來約10至20億元人民幣的收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account